The Acurate neo2 TAVR valve design enhancements include a 60% larger outer sealing skirt to conform to challenging anatomies. This has minimized paravalvular leaks and imporved clinical outcomes compared to the previous-generation Acurate neo Aortic Valve System. #EuroPCR #EuroPCR21 #EuroPCR2021

May 26, 2021 — Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated Boston Scientific Acurate neo2 transcatheter aortic valve replacement (TAVR) system demonstrated positive procedural performance.

May 25, 2021 — Acutus Medical Inc. announced European CE mark approval for a broad suite of electrophysiology (EP) products that includes the AcQCross family of universal transseptal crossing devices, the next generation AcQGuide MAX and VUE large bore delivery sheaths, and the next generation AcQMap EP mapping catheter.

May 25, 2021 — iRhythm Technologies Inc. announced two new U.S. Food and Drug Administration (FDA) 510(k) clearances — one for a new and improved design of its flagship Zio wearable cardiac monitor, and a second for updated artificial intelligence (AI) capabilities. 

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated Balloon (DCB), the first clinical trial in the U.S. to evaluate the safety and effectiveness of a DCB in patients with coronary in-stent restenosis (ISR).

May 19, 2021 — Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm using catheter ablation and those focused on controlling the heart rate using drugs and/or a pacemaker, showed no significant differences in terms of death from any cause or progression of heart failure.

ECMO unit in use to support a severely ill patient at the University of Michigan. ECMO was shown to imporve survival and neuro outcomes in sudden cardiac arrest patients who do not respond to standard therapy.

May 19, 2021 — A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to standard advanced cardiac life support (ACLS), were immediately transported to a cardiac care center and placed on extracorporeal membrane oxygenation (ECMO) were more likely to have survived with good brain function six months later. The outcomes in these patients were better than similar patients who received standard care. 
Cardiovascular information systems (CVIS) allow storage of in-office echocardiograms, aids report generation and reading echos for several hospitals. Hitachi’s VidiStar CVIS.

The ability of a cardiologist to work remotely can save lives. By leveraging the advantages of a cloud-based cardiovascular information system (CVIS), cardiologists can promptly and efficiently assess and recommend an emergency cardio-related treatment plan, regardless of their location relative to the patient.
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021

May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict COVID-19 (SARS-CoV-2) mortality on echocardiograms in an international cardiac ultrasound study of COVID-19 patients.

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction compared with those who had moderately reduced ejection fraction. This was the finding of the GALACTIC-HF trial presented at the American College of Cardiology (ACC) 2021 scientific session.

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 (SARS-CoV-2) who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology (ACC) 2021 Scientific Session. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now